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Re- and Tc-complexes of the oxidation state (1I) offer a useful synthetic pool for the labeling of biomol-
ecules due to their co-ordination properties and stability, which are superior to compounds of the oxida-
tion state (1V). Based on the results for Tc-tricarbonyl complexes it was the topic of this work to develop
an access to similar but higher charged compounds, which could be performed by replacing a neutral
[CO]-group by a [NO]1-group. The resulting Re(I)- and Tc(I)-dicarbonyl-nitrosyl complexes, such as
[N(CH2CH3)4][ReX3(CO)2(NO)], show a tendency for co-ordination at carboxylic and amine groups of
biomolecules (X 5 Br, Cl). This was shown with picolinic acid (H-pic), a suitable model for amino acids,
forming the neutral complex [ReX(pic)(CO)2(NO)]. In a similar fashion conjugation of
[188Re(CO)2(NO)]21—or [99mTc(CO)2(NO)]21 —compounds to proteins or antibodies is feasible. This
approach opens a way to a potentially new class of radiopharmaceuticals.
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INTRODUCTION
The chemistry of rhenium and technetium has re-
ceived much attention due to the importance of
the isotopes Re-188 and Tc-99m for therapeutic
and diagnostic purposes, respectively.1,2 Tc-99m
with a half-life of 6 hours is most attractive for
diagnostic purposes, since it is readily and eco-
nomically available through a 99Mo/99mTc gen-
erator system and has an ideal photon energy. Re-
188 with a half-life of 16.9 hours is also a
generator-produced radioisotope obtained from
an alumina-based 188W/188Re generator system
currently under evaluation for a variety of thera-
peutic applications, including bone pain pallia-
tion and intravascular radiation therapy.3 Com-
plexes of the oxidation state (1V) have been
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widely used since they are easily accessible by
reduction of the corresponding permetallates
[MO4]2 (M 5 188Re, 99mTc), e.g., with SnCl2.
However complexes of the oxidation state (1I)
have not yet been explored to any great extent for
clinical purposes. Since the successful introduc-
tion of [99mTc(CN-R)6]1 in scintigraphy the
chemistry of Re- and Tc-compounds in low oxi-
dation states has become more popular.4 Car-
bonyl compounds with a [M(CO)3]1-moiety es-
pecially, have shown remarkable potential due to
their co-ordination properties, enabling them to
form complexes with nitrogen containing bio-
molecules in high specific activity. They possess
a d6 low-spin electronic configuration and are ki-
netically very stable, since the dissociative ligand
substitution pathway is quantum mechanically
forbidden. Associative substitution is strongly
disfavored because of the lack of metal orbitals
available for additional interaction with donating
or accepting ligands.5 The goals of studies de-
scribed in this paper were to demonstrate the use-
fulness of Re(I)- and Tc(I)-dicarbonyl-nitrosyl
complexes as alternatives to tricarbonyl com-
pounds.
MATERIALS AND METHODS
Although such metal nitrosyl complexes are well
known in organometallic chemistry, they have
not been used in the clinic.6 Their clinical use has
suffered from lack of readily accessible precur-
sors, which could only be obtained under diffi-
cult reaction conditions including high-pressure,
high-temperature, organic solvents and aggres-
sive gases like Cl2 and NO.7 Recently, a conve-
nient synthesis was reported to overcome this
limitation where [99mTc (CO)3(OH2)3]1 was pre-
pared under mild reaction conditions (1 atm CO,
NaBH4, 30 min at 75°C) starting from generator
eluated [99mTcO4]2.8 Tricarbonyl complexes can
now serve as starting materials to generate a
[M(CO)2 (NO)]21-moiety (Fig. 1). For example
[N(CH2CH3)4]2[99mTcX3(CO)3] can easily be
converted into [N(CH2CH3)4][99mTcX3(CO)2
(NO)] with [NO][BF4] in acetonitrile or
dichloromethane (X 5 Br, Cl).9,10
With the synthesis of tricarbonyl complexes
under mild conditions, the promising properties
of the nitrosyl ligand can now be explored for
clinical purposes. [NO]1 is isoelectronic with
CO, but is a better p-acceptor and thus better sta-
bilizes p-donating ligands in the trans-position.
Due to Pearson’s concept of hard and soft acids
and bases (“HSAB” principle) the metal center
becomes harder and acquires a preference for re-
action partners like oxo- or nitrogen-groups.11
So, for example, antibodies or peptides which in-
clude amino acids become possible targets for di-
rect labeling. In addition a nitrosyl ligand, as op-
posed to a carbonyl ligand, causes a bigger split
of the HOMO-LUMO gap, thus increasing the
stability of the complex (HOMO 5 highest oc-
cupied molecular orbital; LUMO 5 lowest unoc-
cupied molecular orbital). Finally, the charge of
the complex is changed by 11 creating new char-
acteristics, for instance, for the co-ordination of
further ligands, biodistribution of labeled com-
pounds or a higher acidity in aqueous solution.
To exemplify the potential of low spin d6 com-
plexes with a [M(CO)2(NO)]21-moiety as a label
for biomolecules, the reaction of [N(CH2CH3)4]
[MX3(CO)2(NO)] with picolinic acid (H-pic) was
investigated in detail (M 5 Re, Tc and X 5 Br,
Cl). Picolinic acid can be considered a suitable
model since it provides two coordinating sites, an
aromatic amine and a carboxylic acid. In fact it
co-ordinates bidentate to the metal center thus
forming [MX(pic)(CO)2(NO)].9,12 Picolinic acid
deprotonates when coordinating to the metal cen-
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Figure 1. Synthesis of [99mTcCl3(CO)2(NO)][N(CH2-CH3)4]
ter and the neutral complex precipitates in water.
The coordination of the bidentate ligand occurs
trans to both carbonyl groups while the position
trans to the nitrosyl group is occupied by a halide
(Fig. 2). In saline solution the position trans to
the NO-ligand in this complex will be occupied
by a chloride.
The same complex could be obtained in a re-
action of [N(CH2CH3)4]2 [MX3(CO)3] with pi-
colinic acid, forming the anionic compound
[N(CH2CH3)4][MX(pic)(CO)3], and subsequent
nitrosylation with [NO] [BF4] in dichlo-
romethane. Substitution of the third CO-group se-
lectively occurs trans to the remaining halide, in-
dicating the preference for a X-M-NO axis with
a p-donating ligand trans to the nitrosyl group as
pointed out above. Crystallization from a mixture
of dichloromethane/hexane yielded yellow crys-
tals that are stable to air and suitable for X-ray
diffraction studies.9,13 An ORTEP drawing is de-
picted in Figure 3.
As expected the Re-CO distance trans to the
acid group of picolinic acid (1.824 Å) is shorter
than that trans to the amine of the heterocycle
(1.991 Å). It is interesting that the Re-CO dis-
tance is even shorter than the Re-NO distance in
the complex (1.893 Å).
Additional experiments with picolinamine
(pica), a ligand which can provide an aromatic
and a primary amine for coordination, showed
similar results, forming the cationic complex
[MX(pica) (CO)2 (NO)]1.9,14 Equal to the com-
plex with picolinic acid the position trans to the
nitrosyl group is occupied by a halide and both
nitrogen groups of the bidentate ligand coordi-
nate trans to the carbonyl groups. Biologically
more relevant ligand systems like histidine and
methionine were also labeled and characterized,
but have not yet been crystallized, thus we didn’t
present them in this paper. Investigations with
analogous sulfur containing ligands have been
presented elsewhere and show further possibili-
ties for direct labeling.15
RESULTS AND DISCUSSION
These results suggest that direct labeling of un-
derivatized antibodies or peptides with certain
188Re- or 99mTc-dicarbonyl-nitrosyl complexes is
feasible, leading to a [MX(Ab)(CO)2(NO)]
radioimmunoconjugate (Ab 5 antibody or pep-
tide). The resulting complexes are expected to be
stable in air and water, which is a major require-
ment for use. As described for Re- and Tc-
tricarbonyl complexes, the small size of the
[M(CO)2(NO)]21-moiety affords minimum in-
terference with the binding site of a biomolecule,
thus increasing the chance it will retain biologi-
cal activity.16 In this way dicarbonyl-nitrosyl
complexes offer a new synthetic pool for direct
labeling of biomolecules.
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Figure 2. Synthesis of [ReX(pic)(CO)2(NO)] (X 5 Br, Cl)
Figure 3. ORTEP drawing of [ReBr(pic)(CO)2(NO)]
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